RECURRENT EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA
Clinical trials for RECURRENT EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New cocktail of drugs targets Tough-to-Treat lung cancer
Disease control OngoingThis early-phase trial tests a combination of three drugs—tazemetostat, topotecan, and pembrolizumab—in 18 adults with small cell lung cancer that has returned after initial treatment. The goal is to find the safest dose and see if the combination can shrink or stabilize the canc…
Matched conditions: RECURRENT EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug combo shows promise for tough lung cancer
Disease control OngoingThis study tests whether combining durvalumab (an immunotherapy) with lurbinectedin (a chemotherapy drug) can help people with advanced small cell lung cancer whose disease returned after standard treatment. About 29 adults who have already had chemotherapy and immunotherapy will…
Matched conditions: RECURRENT EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC